3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Thrombocytopenia
6
Lymphoma, Non-Hodgkin
3
Purpura, Thrombocytopenic, Idiopathic
2
Purpura, Thrombocytopenic
2
Neoplasms
2
Multiple Myeloma
2
Hodgkin Disease
2
Solid Tumor
1
Pancreatic Neoplasms
1
Lymphoma, Mantle-Cell
1
Lymphoma
1
Lung Neoplasms
1
Gastrointestinal Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Oxaliplatin
4
Leucovorin
4
Irinotecan
4
Fluorouracil
4
Capecitabine
3
Bevacizumab
3
cobimetinib
2
Tomography, X-Ray Computed
2
Surveys and Questionnaires
2
Standard of Care
2
Specimen Handling
2
Panitumumab
2
Magnetic Resonance Spectroscopy
2
Ketamine
2
Hydroxychloroquine
2
Cyclophosphamide
2
Cisplatin
2
ulixertinib
1
trifluridine tipiracil drug combination
1
trastuzumab deruxtecan
1
tivozanib
1
sodium thiosulfate
1
rucaparib
1
romiplostim
1
rilotumumab
1
regorafenib
1
pralsetinib
1
ponatinib
1
pembrolizumab
1
osimertinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Gastrointestinal Neoplasms
×
romiplostim
×
Clear all
NCT03362177
2026-02-11
RECITE
Amgen
Phase 3
Completed
165 enrolled
22 charts